Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) EBT (2022 - 2025)

Gossamer Bio's EBT history spans 4 years, with the latest figure at -$47.3 million for Q4 2025.

  • For Q4 2025, EBT fell 33.54% year-over-year to -$47.3 million; the TTM value through Dec 2025 reached -$173.1 million, down 196.11%, while the annual FY2025 figure was -$170.5 million, 206.39% down from the prior year.
  • EBT reached -$47.3 million in Q4 2025 per GOSS's latest filing, up from -$48.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $53.7 million in Q2 2024 to a low of -$59.0 million in Q3 2022.
  • Average EBT over 4 years is -$40.2 million, with a median of -$46.0 million recorded in 2024.
  • Peak YoY movement for EBT: soared 226.29% in 2024, then tumbled 171.32% in 2025.
  • A 4-year view of EBT shows it stood at -$57.2 million in 2022, then rose by 15.85% to -$48.1 million in 2023, then grew by 26.4% to -$35.4 million in 2024, then crashed by 33.54% to -$47.3 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's EBT are -$47.3 million (Q4 2025), -$48.2 million (Q3 2025), and -$38.3 million (Q2 2025).